At a glance
Nectin Therapeutics is a biotechnology company pioneering the development of next-generation immune-oncology (IO) and Antibody Drug Conjugates (ADC) therapies, with the intention to set a new standard for efficacy and patient response rates across various solid and hematological cancers. The company’s research leverages unique insights into the Nectin pathway to address critical escape mechanisms of current IO therapies through a differentiated pipeline of novel monoclonal antibodies (mAbs) and antibody-drug-conjugates.
Investors
Integra Holdings, aMoon, Peregrine and Marius Nacht
